Gyre Pharmaceuticals has completed participant enrolment for its 52-week Phase III clinical trial assessing Pirfenidone ...

Partnership further supports trial recruitment; FORTITUDE-HCM to be highlighted at upcoming HCMA Annual Patient MeetingEnrollment underway for ...

A Dutch study involving more than 1100 men found that the antioxidant supplement Impryl did not improve fertility. The trial, ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand ...

EV25 was generally well-tolerated and demonstrated a good safety profile, with no observable dose-dependent safety trends.

Clarametyx has concluded subject enrolment in its Phase Ib/IIa study of CMTX-101, an immune-enhancing antibody therapy being ...

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

This phase II/III double-blind study assessed efficacy and safety of cediranib with standard chemotherapy as initial therapy for advanced non–small-cell lung cancer (NSCLC). Although all authors ...

Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and ...